“Results from Part 1 Safety Run-in Period of a 2-part, Phase 2, Multicenter, Open-label, Proof-of-Concept Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Subjects with Basal Cell Carcinoma”, J of Skin, vol. 7, no. 6, p. s260, Nov. 2023, doi: 10.25251/skin.7.supp.260.